Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSLPR-CART in Recurrent or Refractory B-ALL
NCT07572136Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of TSLPR-CART in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Nov 2026; status: recruiting.
02
Drugs
TSLPR-CART
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07572136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572136.